DEA Revokes Just Here II Pharmacy’s Registration in Philadelphia

Estimated reading time: 4–6 minutes

Reason for Revocation

On October 24, 2024, the DEA sent Just Here II Pharmacy an Order to Show Cause and Immediate Suspension of Registrations. The order explained that the pharmacy’s actions posed an imminent danger to public health and safety. The DEA said the pharmacy’s recordkeeping and inventory practices for controlled substances were not accurate. This violated federal and Pennsylvania state laws.

According to the DEA, the pharmacy was unable to account for thousands of doses of controlled substances during an audit. This included large discrepancies in the records of drugs like oxycodone, alprazolam, and promethazine with codeine. For example, the DEA found differences of up to 2,930 dosage units for some medications between the pharmacy’s dispensing reports and distributor order data. In some cases, the discrepancies were as high as 100 percent.

Failure to Respond

Just Here II Pharmacy did not respond to the OSC/ISO or request a hearing. The DEA considers this a “default,” meaning the pharmacy is treated as if it admitted to the DEA’s allegations. The OSC/ISO was properly served to the pharmacy’s Pharmacist in Charge.

Controlled Substances Law

The Controlled Substances Act (CSA) and its regulations require pharmacies to keep complete and accurate records of all controlled substances. Both federal and Pennsylvania state law require correct inventory and recordkeeping. Failing to record or maintain accurate data about controlled substances purchases, inventory, or sales breaks these laws.

Investigation Findings

The DEA determined that between September 27, 2023, and March 1, 2024, Just Here II Pharmacy did not keep accurate records. There were significant differences between the pharmacy’s dispensing data and what distributors recorded. This affected several types of controlled substances, such as:

  • Approximately 200 dosage units of oxycodone HCL 5 mg
  • Approximately 1,459 dosage units of oxycodone HCL 15 mg
  • Approximately 2,930 dosage units of alprazolam 2 mg
  • Approximately 2,839 dosage units of promethazine with codeine

The DEA found that the pharmacy failed to maintain required initial and biennial inventories of its stock.

Public Interest Decision

The DEA considered its guidelines for public interest. Factors such as the pharmacy’s experience dispensing controlled substances and its compliance with laws were considered. The DEA found that Just Here II Pharmacy broke both state and federal laws. There was no evidence to show that the pharmacy could be trusted to follow the law in the future.

Since the pharmacy did not participate in the process or accept responsibility, the DEA decided that revoking registration was necessary to protect public health and safety.

Final Order

The Acting Administrator of the DEA, Robert J. Murphy, signed the order on July 8, 2025. The DEA revoked the pharmacy’s registration and denied any pending applications for renewal or modification. The order takes effect on August 13, 2025.

Summary

Just Here II Pharmacy’s DEA registration is revoked. The decision is based on failures to keep correct records for controlled substances and not responding to the DEA’s actions. The DEA says this decision helps protect the public from the risks associated with improper recordkeeping of controlled drugs.


Legal Disclaimer

This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.